Glemderma Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.15 M
- Company Age 6 Year, 2 Months
- Last Filing with ROC 31 Mar 2020
- Revenue Growth %
- Profit Growth 170.82%
- Ebitda 192.95%
- Net Worth 14.30%
- Total Assets 733.00%
About Glemderma Pharmaceutical
Glemderma Pharmaceutical Private Limited (GPPL) is a Private Limited Indian Non-Government Company incorporated in India on 11 December 2018 (Six years and two months 17 days old ). Its registered office is in 24 Parganas, West Bengal, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.15 M, as per Ministry of Corporate Affairs (MCA) records.
Rani Devi, Sarita Devi, Puja Kumari, and One other member serve as directors at the Company.
Company Details
- Location
24 Parganas, West Bengal, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24304WB2018PTC229228
- Company No.
229228
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Dec 2018
- Date of AGM
31 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Who are the key members and board of directors at Glemderma Pharmaceutical?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vikash Singh  | Director | 24-Dec-2018 | Current |
| Rani Devi | Director | 11-Dec-2018 | Current |
| Sarita Devi | Director | 11-Dec-2018 | Current |
| Puja Kumari | Director | 24-Dec-2018 | Current |
Financial Performance of Glemderma Pharmaceutical.
Glemderma Pharmaceutical Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 170.82% increase in profit. The company's net worth Soared by an impressive increase of 14.3%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Glemderma Pharmaceutical?
In 2020, Glemderma Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Dermasons Life Sciences Private LimitedSarita Devi is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Glemderma Pharmaceutical?
Unlock and access historical data on people associated with Glemderma Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Glemderma Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Glemderma Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
